overview rgs

OSTEOARTHRITIS TREATMENT APPEARS TO BE WORKING

Sydney - Thursday - March 27: (RWE Australian Business News) - REGENEUS (RGS) has reported further success with its osteoarthritis treatment called HiQCell.

The regenerative medicine company announced further results from its ethics-approved joint registry used to track the safety and effectiveness of its innovative cell therapy, HiQCell, in the treatment of osteoarthritis.

The interim report of 305 patients at January 23 has found that:

* patients reported continued improvements at 12 months post-treatment;

* the small number of patients (n=7) within the registry that had reached 24 months post-treatment also showed continued improvements;

* patients reported significant improvements in pain, function, sleep quality and reduced usage of pain medications;

* 73pc of patients treated experienced a significant (greater than 30pc) reduction in pain with an average reduction of 79pc across all age groups and osteoarthritis grades; and

* HiQCell is a safe therapy and well-tolerated by patients.

Patients in the registry will continue to be followed for up to five years with analyses updated regularly.

Within the registry a patient is classified as a responder if they report a greater than 30pc reduction in pain.

At 12 months post-treatment 56 of 77 patients were responders and at 24 months post-treatment six of seven patients were responders.

Professor Graham Vesey, CEO of Regeneus, commented, "the joint registry is an important part of the company's commitment to quality.

"Recording patient outcomes over the long term is an example of its perseverance in achieving success."

SHARE PRICE MOVEMENTS

---------------------

Shares of Regeneus yesterday fell 1.5c to 46.5c. Rolling high for the year is 66c and low 24c. The company has 136.3 million shares on issue with a market cap of $463.3 million.

The Joint Registry is a voluntary observational registry and all patients treated with HiQCell are eligible for inclusion.

Patients are tracked from a pre-treatment baseline, at two weeks, at six months and then annually.

Three hundred and five patients had consented to be included in the registry at January 23, representing 77pc of all patients treated.

The Joint Registry has been developed by Regeneus and Professor Jegan Krishnan, chair of Orthopaedic Surgery at the Flinders Medical Centre, Flinders University, Adelaide.

Timing of the report coincides with the treating of the 1,000th joint with HiQCell, comprising knees, hips, ankles, wrists, shoulders and digits across a cohort of over 450 patients.

Dr Donald Kuah, a leading testing Medical practitioner of HiQCell and specialist sports and exercise physician, was very interested in the results.

He remarked, "This registry is extremely valuable as it allows me to track specific outcomes of my own patients as well as being able to observe the treatment effect across all other patients enrolled in the registry."

BACKGROUND

----------

Regeneus Ltd is an Australian regenerative medicine company that develops and commercialises proprietary technologies for the preparation of point-of-care and off-the-shelf cell therapies using adipose (fat) derived regenerative cells including mesenchymal stem cells for the treatment of musculoskeletal and other inflammatory conditions in humans and animals.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine and advanced therapies.

ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organisations.

Prior to the formation of ARM in 2009, there was no advocacy organisation operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community.

Today ARM has more than 150 members and is the leading global advocacy organisation in this field.

NOTE: Today (US time) John Martin, executive chairman of Regeneus, will make a presentation at the second Annual Regen Med Investor Day to be held in New York City.

It has been organised by the Alliance for Regenerative Medicine (ARM) in partnership with financial firms Maxim Group and Piper Jaffray.

The event includes clinical and commercial experts who will be on hand to address specific questions regarding the outlook for the industry, as well as offer insight into how regenerative medicine products could impact the standard of care in key therapeutic areas.

The program will include talks by key opinion leaders in the industry, life science investment experts and analysts as well as presentations by more than 30 leading companies from across the globe.